Dementia Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Dementia is a clinical syndrome characterised by progressive decline in cognitive function — including memory, language, problem-solving, attention, and visuospatial abilities — severe enough to interfere with daily functioning and quality of life. It is not a single disease but a syndrome caused by various underlying neuropathologies. Alzheimer's disease (AD) accounts for 60–80% of cases, followed by vascular dementia (20%), dementia with Lewy bodies (5–10%), and frontotemporal dementia. Worldwide, an estimated 55 million people live with dementia, with 10 million new cases annually.

Although no treatment currently reverses or cures most forms of dementia, significant advances have recently been made in disease-modifying therapies. Lecanemab (Leqembi) and donanemab — anti-amyloid monoclonal antibodies — received FDA approval in 2023 and demonstrated statistically significant slowing of clinical decline in early Alzheimer's disease in Phase 3 trials, marking a historic inflection in treatment possibilities. Symptomatic treatments — acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) and the NMDA receptor antagonist memantine — remain the cornerstone of treatment for established dementia, improving cognitive and functional symptoms in a significant proportion of patients.

Dementia management is inherently multidisciplinary, requiring neurologists, geriatricians, psychiatrists, neuropsychologists, speech therapists, occupational therapists, physiotherapists, social workers, and carers. Person-centred care, carer education and support, environmental adaptation, and management of behavioural and psychological symptoms of dementia (BPSD) are as important as pharmacological treatment.

Dementia treatment addresses the spectrum of dementia syndromes, each with specific approaches. Alzheimer's disease is treated with acetylcholinesterase inhibitors in mild-to-moderate stages, memantine in moderate-to-severe disease, and disease-modifying anti-amyloid therapies (lecanemab, donanemab) in early stages with confirmed amyloid pathology. Vascular dementia management focuses on aggressive cardiovascular risk factor control — blood pressure, diabetes, hyperlipidaemia, atrial fibrillation, and antiplatelet therapy — to prevent progression from new ischaemic events.

Dementia with Lewy bodies responds to acetylcholinesterase inhibitors but requires careful avoidance of conventional antipsychotics that cause severe and potentially life-threatening neuroleptic sensitivity reactions in DLB. Frontotemporal dementia lacks disease-specific pharmacotherapy but benefits from behavioural management and SSRIs for neuropsychiatric symptoms. Normal pressure hydrocephalus (NPH) — characterised by cognitive decline, gait disturbance, and urinary incontinence — is potentially reversible through ventriculoperitoneal shunting, making early identification critical. Mild cognitive impairment (MCI) benefits from intensive vascular risk management and lifestyle interventions reducing conversion to dementia.

Candidates for acetylcholinesterase inhibitor therapy are patients with mild-to-moderate Alzheimer's disease (MMSE 10–26), confirmed by clinical assessment and cognitive testing. Memantine is indicated in moderate-to-severe AD (MMSE below 20) as monotherapy or combined with AChEIs. Disease-modifying anti-amyloid therapies are currently indicated for early-stage AD — mild cognitive impairment due to AD or mild AD dementia — with confirmed amyloid pathology by PET imaging or CSF biomarkers, and without significant microhaemorrhages on MRI.

Contraindications to AChEIs include known hypersensitivity, symptomatic bradycardia or sick sinus syndrome, active peptic ulcer disease, and caution in asthma or COPD. Anti-amyloid therapies carry risk of amyloid-related imaging abnormalities (ARIA) — brain oedema or microhaemorrhages — requiring careful patient selection (APOE ε4 homozygotes have the highest risk), baseline and monitoring MRI scans. Patients must have sufficient cognitive capacity or appropriate surrogate decision-maker support for informed consent to disease-modifying therapies.

Pharmacological management includes acetylcholinesterase inhibitors — donepezil 10 mg daily (the most widely used), rivastigmine patch 9.5–13.3 mg, galantamine 24 mg extended-release — which increase acetylcholine availability by inhibiting its breakdown. They modestly improve cognitive function, activities of daily living, and global clinical impression in mild-to-moderate AD. Memantine (20 mg daily) blocks excessive NMDA receptor glutamate activation, reducing excitotoxicity; it is effective in moderate-to-severe AD. Combination therapy provides additional benefit over either agent alone.

Non-pharmacological interventions are essential evidence-based components. Cognitive stimulation therapy (CST) — structured group cognitive activities delivered twice weekly — has strong RCT evidence for cognitive and quality-of-life improvements in mild-to-moderate dementia, with effect sizes comparable to AChEIs. Individualised physical exercise programmes reduce cognitive decline and neuropsychiatric symptoms. Music therapy, reminiscence therapy, and occupational therapy activities tailored to preserved abilities improve mood, function, and carer wellbeing. Behavioural and psychological symptoms of dementia (BPSD) are addressed through non-pharmacological approaches first; antipsychotics are used only for severe distressing symptoms with explicit risk-benefit discussion, given a documented 1.6–1.7 times increased mortality risk in elderly dementia patients. Disease-modifying therapies targeting amyloid pathology — lecanemab (FDA approved 2023, EMA approved 2024) and donanemab (FDA approved 2024) — represent a paradigm shift for early Alzheimer's disease, reducing amyloid plaque burden and slowing cognitive decline by 27-35% in Phase III trials in carefully selected patients with confirmed amyloid pathology and mild cognitive impairment or mild dementia.

Acetylcholinesterase inhibitors provide clinically meaningful cognitive and functional improvements in approximately 30–40% of treated patients with mild-to-moderate AD; a further 30–40% are stabilised relative to expected natural decline. Memantine reduces agitation, aggression, and cognitive decline in moderate-to-severe AD. The CLARITY-AD trial of lecanemab demonstrated a 27% slowing of clinical decline at 18 months — modest but statistically significant and clinically meaningful for patients and carers in early-stage disease.

Cognitive stimulation therapy demonstrates cognitive score improvements of 1.5–2 MMSE points at 7 weeks — comparable to AChEI benefits. Exercise programmes reduce neuropsychiatric symptoms and improve physical function and independence. From a population perspective, treatments that meaningfully delay nursing home placement or maintain daily independence represent enormous economic and quality-of-life value for patients, their families, and healthcare systems.

Acetylcholinesterase inhibitors commonly cause cholinergic side effects: nausea, vomiting, and diarrhoea, particularly at initiation or dose escalation — managed by dose titration and taking medication with food or at night. Rivastigmine patch causes less gastrointestinal upset than oral formulations. Cardiac effects include bradycardia, first-degree AV block, and rarely syncope, requiring caution in patients with cardiac conduction abnormalities. Memantine is generally well-tolerated; common side effects include dizziness, headache, and constipation.

Anti-amyloid therapies carry a specific risk of ARIA — brain oedema (ARIA-E) or microhaemorrhages (ARIA-H) on MRI — occurring in approximately 21% of lecanemab-treated patients (versus 9% placebo) in the CLARITY-AD trial, with most being asymptomatic. Symptomatic ARIA occurred in 3% of patients and required treatment suspension. Risk is highest in APOE ε4 homozygotes. Mandatory MRI monitoring during treatment is required. Antipsychotics used for BPSD carry a black-box warning for increased mortality, stroke risk, and falls in elderly dementia patients.

Dementia requires lifelong structured management. Clinical review every 6 months assesses cognitive function (MMSE, MoCA), functional abilities, neuropsychiatric symptoms, medication efficacy and tolerability, and carer needs. Annual formal neuropsychological assessment tracks progression. Medication efficacy is assessed at 3–6 months — if no cognitive stabilisation or functional benefit is evident, dose optimisation or medication change is considered.

Advance care planning — while the patient retains capacity — should be initiated early: addressing future care wishes, financial power of attorney, driving cessation (mandatory at a defined level of impairment), and end-of-life preferences. Falls prevention, continence management, nutritional support, and sleep hygiene become increasingly important as disease progresses. Social care planning including respite services, day centres, and eventually specialist dementia nursing home placement is part of long-term care coordination.

Dementia imposes enormous economic costs. Annual direct medical costs in the US for a person with dementia average USD 28,000–48,000; specialist memory care facilities cost USD 60,000–100,000+ per year. Novel disease-modifying therapies (lecanemab US list price approximately USD 26,500 per year) add significant drug costs. MRI monitoring for anti-amyloid therapy adds further expense.

In countries with universal healthcare (UK NHS, Canada), dementia drugs are subsidised and memory clinic services are accessible without direct cost. Patients in Asia with family carers can access high-quality geriatric and neurology specialist services in India, Thailand, and Malaysia at USD 50–200 per consultation versus USD 500–1,500 in the US. The primary cost driver globally is residential and carer costs, not pharmacotherapy — family-centred home care in lower-income countries can substantially reduce overall costs.

No dietary supplement or alternative medicine product has strong RCT evidence for preventing or treating dementia. However, modifiable lifestyle risk factors — physical inactivity, smoking, excessive alcohol, hypertension, diabetes, obesity, hearing loss, depression, social isolation, and air pollution — account for approximately 40% of dementia cases globally (Lancet Commission, 2024). Lifestyle modification and risk factor management represent the most powerful available preventive interventions.

Vascular risk factor control — blood pressure below 130/80 mmHg in midlife, statin therapy, diabetes management — is the cornerstone of vascular dementia prevention. Structured exercise (150 minutes moderate-intensity per week) reduces dementia risk by 30–35% in large cohort studies. Hearing aid use in people with age-related hearing loss reduces the hearing-loss-attributable cognitive decline. Mediterranean and MIND diets are associated with slower cognitive decline in observational studies, though RCT evidence is less consistent. These preventive strategies must be prioritised alongside pharmacological treatment.